Compliance Trainings addresses a variety of pivot points that includes the communication of most recent updates in regulatory compliance arena and best practices.
Online PR News – 17-January-2014 – Mississauga – Scheduled On : Thursday, January 23, 2014 at 13:00 Hrs
The Generic Drug User Fee Amendments of 2012 (GDUFA) were designed to speed the delivery of safe and effective generic drugs to the public and reduce costs to industry. A Drug Master File (DMF) is a submission to the Food and Drug Administration (FDA) that may be used to provide confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of one or more human drugs. This webinar will discuss the effect of GDUFA on the DMF process.
Although a DMF submission is not required by law or FDA regulation, it is often created to permit the FDA to review information in support of a third party’s submission without revealing the contents of the file to the third party. This maintains the confidentiality of proprietary information. DMFs usually cover the Chemistry, Manufacturing and Controls (CMC) of a drug product component (e.g., drug substance). The information contained in a DMF may be used to support an Investigational New Drug Application (IND), a New Drug Application (NDA), an Abbreviated New Drug Application (ANDA), another DMF, an Export Application, or amendments and supplements to any of these.
GDUFA enables FDA to assess user fees and bring greater predictability to the review of generic drug applications. The law requires industry to pay user fees to supplement the costs of reviewing generic drug applications and inspecting facilities. Additional resources enable FDA to reduce a current backlog of pending applications, cut the average time required to review generic drug applications for safety, and increase risk-based inspections. It is important to have an understanding of GDUFA and the new fees and requirements DMF holders must fulfill in order to achieve “Available for Reference” status. Only Abbreviated New Drug Application (ANDA) submissions which reference “Available for Reference” API DMFs can be received by FDA. Not having clarity on the new fees and requirements could cost your organization time, money, and other critical resources.
This webinar will help you have a better understanding of GDUFA, its implications regarding DMFs, who in industry is impacted, the required fees, and achieving DMF “Available for Reference” status.
Areas Covered in the Session :
• GDUFA background
• Key definitions
• Who in industry is impacted
• Self-identification and fee requirements
• New DMF correspondences and meetings
• Completeness assessments
• “Available for Reference” status
Who Will Benefit:
• Regulatory Affairs professionals
• Project Managers
• QA & QC Managers
• API manufacturers
• Generic drug manufacturers
• Type II (API) DMF holders
• ANDA sponsors
• Any individuals interested in the generic drug industry